Lichen planus – A refractory autoimmune disorder


Review Article

Author Details : G . Manmohan, K Aishwarya Yadav, G Madhulika, Sunil Chaudhry*

Volume : 9, Issue : 1, Year : 2023

Article Page : 20-27

https://doi.org/10.18231/j.ijced.2023.003



Suggest article by email

Get Permission

Abstract

Lichen planus (LP) is a chronic inflammatory mucocutaneous disease of unknown aetiology with an estimated incidence of 0.5%–4.0% having a female preponderance at a ratio of 1.5:1. Oral lichen planus (OLP) is commoner than the cutaneous form and tends to be more persistent and more refractory to the treatment. The prevalence of oral lichen planus in Indian population is around 3% with more female predilection. Oral lesions occur in 50%–70% of the patients with lichen planus. LP is considered to be a T-cell-mediated autoimmune skin disease, in which CD8+ cytotoxic T lymphocytes are major mediators. TNF-? and IL-10, interferon-gamma (IFN-?), IL-4, and IL-8, have been suggested to have an important role in the pathogenesis of OLP. The complications of Lichen Planus include post-inflammatory hyperpigmentation, scarring alopecia, dyspareunia, oesophageal stenosis & possible malignant transformation. Mucocutaneous site biopsy can confirm the diagnosis when taken from the edge of a plaque. There is no cure for Lichen Planus, the management is often performed with the use of antihistamines, corticosteroids, retinoids, immunomodulators, phototherapy and immunosuppressives. Inconsistent results are shown by griseofulvin and chloroquine derivatives. (further prospective studies are needed).
 

Keywords: Oral lichen planus (OLP), Autoimmune, Steroids, Methotrexate, Tacrolimus, Phototherapy, Surgical excision, Laser usage


How to cite : Manmohan G ., Yadav K A, Madhulika G, Chaudhry S, Lichen planus – A refractory autoimmune disorder. IP Indian J Clin Exp Dermatol 2023;9(1):20-27


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.







Article History

Received : 25-01-2023

Accepted : 04-03-2023


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijced.2023.003


Article Metrics






Article Access statistics

Viewed: 1577

PDF Downloaded: 221



Medical Abbreviation List